Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2021 | Key trials in CTCL

Lauren Pinter-Brown • 27 Aug 2021
SOHO 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Antibodies Bexarotene Brentuximab vedotin Methotrexate Mogamulizumab Vorinostat
ALCANZA MAVORIC

Lauren Pinter-Brown, MD, of UCI Health, Chao Family Comprehensive Cancer Center, Orange, CA, talks on a response criterion for clinical trials assessing treatments for cutaneous T-cell lymphoma (CTCL) which 3 contemporary trials have utilized and outlines these trials. Dr Pinter-Brown talks on the Phase III ALCANZA study (NCT01578499) of brentuximab vedotin versus methotrexate or bexarotene and the Phase III MAVORIC study (NCT01728805) on mogamulizumab versus vorinostat for relapsed/refractory CTCL. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

More from Lauren Pinter-Brown

1:16
Treatment of advanced CTCL in 2021
Lauren Pinter-Brown • 27 Aug 2021
1:53
Improving clinical knowledge of CTCL
Lauren Pinter-Brown • 27 Aug 2021
1:15
Risk stratification for CTCL
Lauren Pinter-Brown • 27 Aug 2021
1:24
CTCL management: the challenges faced by clinicians
Lauren Pinter-Brown • 27 Aug 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals